Advertisement

Therapeutic radiopharmaceuticals

  • Azuwuike Owunwanne
  • Mohan Patel
  • Samy Sadek

Abstract

There are three types of radiation for therapy: external beam, implantation of radioactive sources and orally or parenterally administered radiopharmaceuticals. This chapter is concerned with the third type. Within the last decade, there has been an increasing interest in developing new radiopharmaceuticals for therapy, especially those used for palliation of pain from bone metastases. 32P-chromic phosphate, 32P-sodium phosphate, 89Sr-strontium chloride, 153Sm-ethylenediaminetetramethy-lene phosphonate (153Sm-EDTMP) and 186Re-1, 1-hydroxyethylidene diphosphonate (186Re-HEDP) are described in this chapter. 131I sodium iodide and 131I-mIBG were covered in Chapter 8.

Keywords

Polycythemia Vera Phosphonic Acid Osseous Metastasis Bone Cancer Pain Gentisic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McAfee, J.G. and Subramanian, G. (1975) Radioactive agents for imaging, in Clinical Scintillation Imaging (eds M.L. Freeman and P.M. Johnson), Grune & Stratton, New York, p. 28.Google Scholar
  2. 2.
    ICRP Publication No. 53 (1990) Radiation Dose to Patients from Radiopharmaceuticals, Pergamon Press, Oxford, p. 84.Google Scholar
  3. 3.
    Volkert, W.A., Goeckeleer, W.F. and Ehrhardt, G.J. (1991) Therapeutic radionuclides, production and decay property considerations. J. Nucl. Med., 32, 174–85.Google Scholar
  4. 4.
    Robinson, R.G., Blake, G.M., Preston, D.F. et al (1989) Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics, 9, 271–81.Google Scholar
  5. 5.
    Blake, G.M., Zivanovic, M.A., Blaquiere, R.M. et al. (1988) Strontium-89 therapy: Measurement of absorbed dose to skeletal metastases. J. Nucl. Med., 29, 549–57.Google Scholar
  6. 6.
    Blake, G.M., Zivanovic, M.A., McEwan, A.J. et al. (1986) Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur. J. Nucl. Med., 12, 447–54.Google Scholar
  7. 7.
    Silberstein, E.B. and Williams, C. (1985) Strontium-89 therapy for the pain of osseous metastases. J. Nucl Med., 26, 345–48.Google Scholar
  8. 8.
    Breen, S.L., Powe, J.E. and Ponter, A.T. (1992) Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.J. Nucl. Med., 33, 1316–23.Google Scholar
  9. 9.
    Dickinson, C.Z. and Hendrix, N.S. (1993) Strontium-89 therapy in painful bony metastases. J. Nucl. Med. Technol., 21, 133–37.Google Scholar
  10. 10.
    ICRP Publication No. 53 (1990) Radiation Dose to Patients from Radiopharmaceuticals, Pergamon Press, Oxford, p. 171.Google Scholar
  11. 11.
    Goeckeler, W.F., Edwards. B., Volkert, W.A. et al. (1987) Skeletal localization of Sm-153 chelates: potential therapeutic bone agents. J. Nucl. Med., 28, 495–504.Google Scholar
  12. 12.
    Volkert, W.A., Simar, J., Ketring, A.R. et al (1989) Radiolabeled phosphonic acid chelates: potential therapeutic agents for treatment of skeletal metastases. Drug Future, 14, 799–811.Google Scholar
  13. 13.
    Moedritzer, K. and Irani, R.R. (1966) The direct synthesis of α-amino-methyl phosphonic acids. Mannich-type reactions with orthophosphor-ous acid. J. Org. Chem., 31, 1603–07.CrossRefGoogle Scholar
  14. 14.
    Singh, A., Holmes, R.A., Farhangi, M. et al (1989) Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J. Nucl. Med., 30, 1814–18.Google Scholar
  15. 15.
    Turner, J.H., Martindale, A.A., Sorby, P. et al (1989) Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur. J. Nucl. Med., 15, 784–95.CrossRefGoogle Scholar
  16. 16.
    Francis, M.D., Russel, R.G.G. and Fleish, H. (1969) Diphosphonate inhibits formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science, 165, 1264–66.CrossRefGoogle Scholar
  17. 17.
    Lattimer, J.C., Corwin, L.A., Stapleton, J. et al (1990) Clinical and clinicopathologic effects of samarium-153 EDTMP administered intravenously in normal dogs. J. Nucl. Med., 31, 586–93.Google Scholar
  18. 18.
    Holmes, R.A. (1992) [153Sm] EDTMP: potential therapy for bone cancer pain. Semin. Nucl. Med., 22, 41–5.CrossRefGoogle Scholar
  19. 19.
    Appelbaum, F.R., Sandmaier, B., Brown, P. et al (1980) Myelosuppression and mechanism of recovery following administration of 153Sm EDTMP. Antibody Immunoconj. Radiopharmacol., 1, 263–70.Google Scholar
  20. 20.
    Farhangi, M., Holmes, R.A., Volkert, W.A. and Singh, A. (1987) 153Sm EDTMP. A potential ra-diotherapeutic agent for metastatic bone cancer (abstract). Am. Soc. Clin. Oncol Proc., 6, 22.Google Scholar
  21. 21.
    Eary, J.F., Collins, C., Stabin, M. et al (1993) Samarium-153 EDTMP biodistribution and dosimetry estimation. J. Nucl. Med., 34, 1031–36.Google Scholar
  22. 22.
    Castronovo, F.P. (1974) Method for the synthesis of 1-hydroxyethylidene-1, 1-di-sodium phosphonate (HEDSPA): a skeletal seeking radiopharmaceutical after labeling with Tc-99m. J. Nucl Med., 15, 127–30.Google Scholar
  23. 23.
    Pipes, D.W. and Deutsch, E. (1993) Rhenium Re-186 Etidronate injection. Drug Future, 18, 520–24.Google Scholar
  24. 24.
    deKlerk, J.M.H., Van Dijk, A., Vanhet Schip, A.D. et al (1992) Pharmacokinetics of rhenium-186 after administration of rhenium-186 HEDP to patients with bone metastases. J. Nucl. Med., 33, 646–51.Google Scholar
  25. 25.
    Maxon, H.R., Deutsch, E.A., Thomas, S.R. et al (1988) Re-186 (Sn) HEDP for treatment of multiple metastatic foci in bone: human biodis-tribution and dosimetric studies. Radiology, 166, 501–7.Google Scholar

Copyright information

© Azuwuike Owunwanne, Mohan Patel and Samy Sadek 1995

Authors and Affiliations

  • Azuwuike Owunwanne
    • 1
  • Mohan Patel
    • 2
  • Samy Sadek
    • 3
  1. 1.Department of Nuclear Medicine, Faculty of MedicineKuwait UniversityKuwait
  2. 2.Kuwait Central Radiopharmacy Kuwait Cancer Control CenterMinistry of Public HealthKuwait
  3. 3.Department of Nuclear Medicine Faculty of MedicineKuwait UniversityKuwait

Personalised recommendations